Skip to content
Home » COVID-19 vaccine tracker | RAPS

COVID-19 vaccine tracker | RAPS


Posted 06 Might 2022 | By Jeff Craven 

COVID-19 vaccine tracker
The worldwide endeavor to create a protected and efficient COVID-19 vaccine is bearing fruit. Dozens of vaccines now have been licensed or authorised across the globe; many extra stay in improvement.
To make clear the panorama for our readers, our vaccine tracker has been cut up in two. The primary chart particulars vaccine candidates which are nonetheless in improvement to handle the shortage of vaccines and entry in lots of international locations around the globe; the second chart lists vaccines which are licensed or authorised by a number of nation. To disclose in-depth details about every candidate, choose the “Particulars” button above the chart or click on on the inexperienced plus button subsequent to every entry.
Details about the unprecedented public/non-public partnerships spawned by the COVID-19 public well being emergency now could be discovered under the charts.
Our charts are up to date each different week. For those who want to submit an replace or discover a problem with this knowledge, please e-mail Focus at [email protected]

Up to date 06 Might with new data on vaccines from Pfizer/BioNTech, Moderna, Bharat Biotech, Zydus Cadila, Novavax, Medicago and Valneva.


Vaccine candidates in improvement



Approved/authorised vaccines




COVID-19 vaccine initiatives

OWS: Operation Warp Velocity is a collaboration of a number of US authorities departments together with Well being and Human Companies (HHS) and subagencies, Protection, Agriculture, Vitality and Veterans Affairs and the non-public sector. OWS has funded JNJ-78436735 (Janssen), mRNA-1273 (Moderna), and NVX‑CoV2373 (Novavax), V590 (Merck/IAVI), V591 (Merck/Themis), AZD1222 (AstraZeneca/College of Oxford), and the candidate developed by Sanofi and GlaxoSmithKline.
OWS is “a part of a broader technique to speed up the event, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics.” 
ACTIV: Inside OWS, the US Nationwide Institutes of Well being (NIH) has partnered with greater than 18 biopharmaceutical firms in an initiative referred to as ACTIV. ACTIV goals to fast-track improvement of drug and vaccine candidates for COVID-19.
COVPN: The COVID-19 Prevention Trials Community (COVPN) combines scientific trial networks funded by the Nationwide Institute of Allergy and Infectious Ailments (NIAID): the HIV Vaccine Trials Community (HVTN), HIV Prevention Trials Community (HPTN), Infectious Ailments Scientific Analysis Consortium (IDCRC), and the AIDS Scientific Trials Group.
COVAX: The COVAX initiative, a part of the World Well being Group’s (WHO) Entry to COVID-19 Instruments (ACT) Accelerator, is being spearheaded by the Coalition for Epidemic Preparedness Improvements (CEPI); Gavi, the Vaccine Alliance; and WHO. The aim is to work with vaccine producers to supply low-cost COVID-19 vaccines to international locations. CEPI’s candidates from firms Inovio, Moderna, CureVac, Institut Pasteur/Merck/Themis, AstraZeneca/College of Oxford, Novavax, College of Hong Kong, Clover Biopharmaceuticals, and College of Queensland/CSL are a part of the COVAX initiative. The US joined COVAX on 21 January. Probably the most up-to-date forecast of COVAX’s vaccine provide could be discovered right here. An interim distribution forecast, most not too long ago printed 3 February, could be discovered right here.


© 2022 Regulatory Affairs Professionals Society.


Supply hyperlink